Attached files

file filename
EX-14.1 - EXHIBIT 14.1 CODE OF BUSINESS CONDUCT AND ETHICS - AXIM BIOTECHNOLOGIES, INC.f10q093017_ex14z1.htm
EX-99.3 - EXHIBIT 99.3 AUDIT COMMITTEE CHARTER - AXIM BIOTECHNOLOGIES, INC.f10q093017_ex99z3.htm
EX-99.2 - EXHIBIT 99.2 COMPENSATION COMMITTEE CHARTER - AXIM BIOTECHNOLOGIES, INC.f10q093017_ex99z2.htm
EX-99.1 - EXHIBIT 99.1 NOMINATION COMMITTEE CHARTER - AXIM BIOTECHNOLOGIES, INC.f10q093017_ex99z1.htm
EX-32.1 - EXHIBIT 32.1 SECTION 906 CERTIFICATION - AXIM BIOTECHNOLOGIES, INC.f10q093017_ex32z1.htm
EX-31.2 - EXHIBIT 31.2 SECTION 302 CERTIFICATION - AXIM BIOTECHNOLOGIES, INC.f10q093017_ex31z2.htm
EX-31.1 - EXHIBIT 31.1 SECTION 302 CERTIFICATION - AXIM BIOTECHNOLOGIES, INC.f10q093017_ex31z1.htm
10-Q - FORM 10-Q QUARTERLY REPORT - AXIM BIOTECHNOLOGIES, INC.f10q093017_10q.htm

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Report of AXIM Biotechnologies, Inc., a Nevada Corporation, (the “Company”) on Form 10- for the period ended September 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned certify the following pursuant to Section 18, U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002:

 

1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.

The information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

November 17, 2017

 

/s/ Robert Malasek

Robert Malasek

Chief Financial Officer

Principal Financial Officer